The Claim
Tirzepatide reduces all-cause mortality by 16% compared to dulaglutide in adults with type 2 diabetes and established cardiovascular disease over a median follow-up of 47 months, with a hazard ratio of 0.84 (95% CI, 0.75–0.94).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes and heart disease, tirzepatide is associated with a 16% lower risk of death from any cause over about four years compared to dulaglutide.
See the scientific wording
Tirzepatide reduces all-cause mortality by 16% compared to dulaglutide in adults with type 2 diabetes and established cardiovascular disease over a median follow-up of 47 months, with a hazard ratio of 0.84 (95% CI, 0.75–0.94).
Tirzepatide helps the body use insulin better and lose weight, which lowers blood sugar and reduces strain on the heart and blood vessels, making it less likely for someone with diabetes and heart disease to die from heart or circulation problems.
What the research says
1 studyIn people with type 2 diabetes and heart disease, tirzepatide helped lower the chance of dying from any cause by about 16% compared to another common diabetes drug, dulaglutide, over nearly four years.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.